CytoMed Therapeutics Limited (GDTC) Return on equity 2024–2025
CytoMed Therapeutics Limited (GDTC) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-60.8%FY2025 · since FY2024: -28.1% → -60.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -60.8% | -32.8 pp |
| FY2024 | -28.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More GDTC financial trends
GDTC RevenueGDTC Net incomeGDTC Net marginGDTC Gross profitGDTC Gross marginGDTC Operating incomeGDTC Operating marginGDTC Operating cash flowGDTC Free cash flowGDTC Capital expendituresGDTC Stock buybacksGDTC Dividends paidGDTC Total assetsGDTC Total liabilitiesGDTC Shareholders’ equityGDTC overview →